Medical Oncology

, Volume 26, Issue 4, pp 452–459 | Cite as

Risk of subsequent dementia diagnoses does not vary by types of adjuvant chemotherapy in older women with breast cancer

  • Mukaila A. Raji
  • Lynsey P. Tamborello
  • Yong-Fang Kuo
  • Hyunsu Ju
  • Jean L. Freeman
  • Dong D. Zhang
  • Sharon H. Giordano
  • James S. Goodwin
Original Paper


Objective Little is known about long-term cognitive side effects of adjuvant chemotherapy for breast cancer. We thus examined incidence of dementia diagnoses in older women diagnosed with breast cancer, stratified by types of chemotherapy regimen. Methods We identified patients with incident dementia diagnoses through Medicare claims linked to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) tumor registry data. The study population (n = 6,932) consisted of women at least 68 years of age, who were diagnosed with early-stage breast cancer from 1994 through 2002 in one of the SEER areas and received chemotherapy as part of their cancer treatment. Excluded were women with a diagnosis of dementia within the 3 years prior to their cancer diagnosis. Results Our sample comprised mostly white women. The mean age was 74. Fifty-seven percent were estrogen receptor positive. Over 70% had no comorbidity. The use of taxol and anthracycline-based treatments increased from mid-1990s to early 2000. Increasing age at cancer diagnosis, Black ethnicity, living in a census tract with lower level of education, and increasing number of comorbidities were associated with new claims of dementia diagnoses after chemotherapy. There was no significant association between types of chemotherapy agents and risk of subsequent dementia diagnoses. Conclusion No association was found between types of adjuvant chemotherapy agents for breast cancer and risk of new dementia diagnoses. Our findings suggest that concerns about post-chemotherapy dementia should not be a major factor in determining type of adjuvant chemotherapy regimen to prescribe for older women with breast cancer.


Breast cancer Oncology Dementia Chemotherapy Aging 


  1. 1.
    Early Breast Cancer Trialists’ CollaborativeGroup (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717. doi:10.1016/S0140-6736(05)66544-0.CrossRefGoogle Scholar
  2. 2.
    Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828–34. doi:10.1038/sj.bjc.6603029.CrossRefPubMedGoogle Scholar
  3. 3.
    Goldhirsch A, William C, Wood WC, Richard D, Gelber RD, Alan S, et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol. 2003;21(17):3357–65. doi:10.1200/JCO.2003.04.576.CrossRefPubMedGoogle Scholar
  4. 4.
    Scherwath A, Mehnert A, Schleimer B, et al. Neuropsychological function in high- risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol. 2006;17:415–23. doi:10.1093/annonc/mdj108.CrossRefPubMedGoogle Scholar
  5. 5.
    Ferguson RJ, Ahles TA. Low neuropsychological performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep. 2003;3(3):215–22. doi:10.1007/s11910-003-0081-2.CrossRefPubMedGoogle Scholar
  6. 6.
    Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology. 1995;4:61–6. doi:10.1002/pon.2960040108.CrossRefGoogle Scholar
  7. 7.
    Crivellari D, Bonetti M, Castiglione-Gertsch M. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Study Group Trial VII. J Clin Oncol. 2001;18:1412–22.Google Scholar
  8. 8.
    Hurria A, Brogan K, Panageas KS, Pearce C, Norton L, Jakubowski A, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2005;92:151–6. doi:10.1007/s10549-005-1410-8.CrossRefPubMedGoogle Scholar
  9. 9.
    Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100:2292–9. doi:10.1002/cncr.20272.CrossRefPubMedGoogle Scholar
  10. 10.
    Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004;22:2233–9. doi:10.1200/JCO.2004.08.094.CrossRefPubMedGoogle Scholar
  11. 11.
    Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs M, et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient’s perspective. Breast Cancer Res Treat. 2006;98(3):343–8. doi:10.1007/s10549-006-9171-6.Google Scholar
  12. 12.
    Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol. 2007;25(17):2455–63.CrossRefPubMedGoogle Scholar
  13. 13.
    Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9:967–82. doi:10.1017/S1355617703970019.CrossRefPubMedGoogle Scholar
  14. 14.
    Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer. 2005;104:2222–33. doi:10.1002/cncr.21469.CrossRefPubMedGoogle Scholar
  15. 15.
    Fallet MG, Sanfilippo A, Maruff P, Wlh L, Phillip KA. The nature and severity of cognitive impairment associated with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60–70. doi:10.1016/j.bandc.2005.05.001.CrossRefGoogle Scholar
  16. 16.
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485–93. doi:10.1200/JCO.20.2.485.CrossRefPubMedGoogle Scholar
  17. 17.
    Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology. 2006;15:422–30. doi:10.1002/pon.964.CrossRefPubMedGoogle Scholar
  18. 18.
    van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:210–8. doi:10.1093/jnci/90.3.210.CrossRefPubMedGoogle Scholar
  19. 19.
    Schagen SB, van Dam FSAM, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85(3):640–50. doi:10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G.CrossRefPubMedGoogle Scholar
  20. 20.
    Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn S, Rodenhuis S, et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol. 2002;13:1387–97. doi:10.1093/annonc/mdf241.CrossRefPubMedGoogle Scholar
  21. 21.
    Schagen SB, Muller MJ, Boogerd W, et al. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst. 2006;98:1742–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy. 2003;49:92–104. doi:10.1159/000069773.CrossRefPubMedGoogle Scholar
  23. 23.
    Wefel JS, Kayle AE, Meyers CA. Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target. Br J Cancer. 2004;90(9):1691–6.PubMedGoogle Scholar
  24. 24.
    Keime-Guibert F, Napolitano MJ-Y, Delattre J-Y. Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998;245(11):695–708. doi:10.1007/s004150050271.CrossRefPubMedGoogle Scholar
  25. 25.
    Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MHN, Olver IN, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999;17(8):2355–64.PubMedGoogle Scholar
  26. 26.
    Vardy J, Wong K, Yi Q, Park A, Maruff P, Wagner L, et al. Assessing cognitive function in cancer patients. Support Care Cancer. 2006;14(11):1111–8. doi:10.1007/s00520-006-0037-6.CrossRefPubMedGoogle Scholar
  27. 27.
    Downie FP, Fan HG, Houédé-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006;15(10):921–30. doi:10.1002/pon.1035.CrossRefPubMedGoogle Scholar
  28. 28.
    Schiff D, Wen P. Central nervous system toxicity from cancer therapies. Hematol Oncol Clin N. 2006;20:1377–99. doi:10.1016/j.hoc.2006.09.004.CrossRefGoogle Scholar
  29. 29.
    Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Incidence—SEER 9 Regs Public-Use, Nov 2004 Sub (1973–2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006, based on the November 2005 submission.
  30. 30.
    Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, et al. SEER cancer statistics review, 1975–2000. Bethesda, MD: USA National Cancer Institute; 2004. p. 748.Google Scholar
  31. 31.
    Taylor DH, Fillenbaum GG, Ezell ME. The accuracy of Medicare claims data in identifying Alzheimer’s disease. J Clin Epidemiol. 2002;55:929–37. doi:10.1016/S0895-4356(02)00452-3.CrossRefPubMedGoogle Scholar
  32. 32.
    Potosky AL, Warren JL, Riedel MA, Klabunde CN, Earle CC, Begg CB. Measuring complications of cancer treatment using the SEER-Medicare data. Med Care. 2002;40 Suppl:IV-62–8.Google Scholar
  33. 33.
    Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for services research using a linked medicare-tumor registry database. Med Care. 1993;31:732–48. doi:10.1097/00005650-199308000-00006.CrossRefPubMedGoogle Scholar
  34. 34.
    Giordano SH, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24(18):2750–6. doi:10.1200/JCO.2005.02.3028. Jun 20.CrossRefPubMedGoogle Scholar
  35. 35.
    Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care. 2002;40:26–35. doi:10.1097/00005650-200208001-00004.CrossRefGoogle Scholar
  36. 36.
    Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8):IV-55–61.Google Scholar
  37. 37.
    Du X, Goodwin JS. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer. 2001;92(4):730–7. doi:10.1002/1097-0142(20010815)92:4<730::AID-CNCR1376>3.0.CO;2-P.CrossRefPubMedGoogle Scholar
  38. 38.
    Harris Y, Gorelick PB, Freels S, Billingsley M, Brown N, Robinson D. Neuroepidemiology of vascular and Alzheimer’s dementia among African-American women. J Natl Med Assoc. 1995;87(10):741–5.PubMedGoogle Scholar
  39. 39.
    Tang MX, Cross P, Andrews H, Jacobs DM, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56(1):49–56.PubMedGoogle Scholar
  40. 40.
    Kivipelto M, et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5(9):735–41. doi:10.1016/S1474-4422(06)70537-3.CrossRefPubMedGoogle Scholar
  41. 41.
    Newcomer R, Clay T. Misclassification and selection bias when identifying Alzheimer’s disease solely from Medicare claims records. J Am Geriatr Soc. 1999;47:215–9.PubMedGoogle Scholar
  42. 42.
    Taylor DH Jr., Sloan FA, Doraiswamy PM. Marked increase in Alzheimer’s disease identified in Medicare claims records between 1991 and 1999. J Gerontol A Biol Sci Med Sci. 2004;59:762–6.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Mukaila A. Raji
    • 1
  • Lynsey P. Tamborello
    • 1
  • Yong-Fang Kuo
    • 1
  • Hyunsu Ju
    • 1
  • Jean L. Freeman
    • 1
  • Dong D. Zhang
    • 1
  • Sharon H. Giordano
    • 2
  • James S. Goodwin
    • 1
  1. 1.Department of Internal Medicine, Sealy Center on AgingUniversity of Texas Medical BranchGalvestonUSA
  2. 2.Department of Breast Medical OncologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations